137,875 Shares in ADMA Biologics Inc $ADMA Acquired by Vident Advisory LLC

Key Points

• Vident Advisory LLC has acquired approximately 137,875 shares of ADMA Biologics Inc, valued at around $2.735 million, marking a notable institutional investment in the company.
• ADMA Biologics reported a quarterly earnings increase, with a 15% rise in EPS from the previous year, achieving $0.15 EPS and revenue of $121.98 million, surpassing analyst expectations.
• Insider trading has seen significant activity, with directors selling 455,621 shares for a total of approximately $9.46 million in the last quarter, indicating a decrease in insider ownership.

Vident Advisory LLC purchased a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 137,875 shares of the biotechnology company's stock, valued at approximately $2,735,000. Vident Advisory LLC owned about 0.06% of ADMA Biologics as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of ADMA. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of ADMA Biologics during the 1st quarter worth about $35,000. SVB Wealth LLC acquired a new stake in ADMA Biologics in the 1st quarter valued at about $35,000. Smartleaf Asset Management LLC raised its holdings in ADMA Biologics by 161.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 2,418 shares of the biotechnology company's stock valued at $49,000 after acquiring an additional 1,493 shares during the last quarter. Tsfg LLC acquired a new stake in ADMA Biologics in the 1st quarter valued at about $51,000. Finally, Brooklyn Investment Group raised its holdings in ADMA Biologics by 28,655.6% in the 1st quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company's stock valued at $51,000 after acquiring an additional 2,579 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.

ADMA Biologics Trading Up 0.1%

Shares of NASDAQ ADMA traded up $0.01 during midday trading on Thursday, reaching $16.91. 4,346,426 shares of the stock were exchanged, compared to its average volume of 3,137,782. The company has a 50 day simple moving average of $17.73 and a 200 day simple moving average of $18.92. The stock has a market capitalization of $4.04 billion, a P/E ratio of 19.66 and a beta of 0.54. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.78 and a current ratio of 5.33. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. The business had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business's revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.13 EPS. As a group, equities analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on the stock. Wall Street Zen downgraded shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial increased their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. One analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company. Based on data from MarketBeat.com, ADMA Biologics currently has an average rating of "Buy" and an average price target of $27.67.

Insider Buying and Selling

In related news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the transaction, the director owned 94,830 shares of the company's stock, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the transaction, the director directly owned 478,194 shares of the company's stock, valued at $10,190,314.14. The trade was a 2.05% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 455,621 shares of company stock valued at $9,461,633. Company insiders own 3.70% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.